Literature DB >> 21390107

Vaccinate for the next H2N2 pandemic now.

Gary J Nabel1, Chih-Jen Wei, Julie E Ledgerwood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21390107     DOI： 10.1038/471157a

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Vaccinate before the next pandemic?

Authors:  Klaus Stöhr
Journal:  Nature       Date:  2010-05-13       Impact factor: 49.962

2.  Evaluation of replication and cross-reactive antibody responses of H2 subtype influenza viruses in mice and ferrets.

Authors:  Grace L Chen; Elaine W Lamirande; Chin-Fen Yang; Hong Jin; George Kemble; Kanta Subbarao
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus.

Authors:  Rui Xu; Damian C Ekiert; Jens C Krause; Rong Hai; James E Crowe; Ian A Wilson
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

4.  Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design.

Authors:  Chih-Jen Wei; Jeffrey C Boyington; Kaifan Dai; Katherine V Houser; Melissa B Pearce; Wing-Pui Kong; Zhi-Yong Yang; Terrence M Tumpey; Gary J Nabel
Journal:  Sci Transl Med       Date:  2010-03-24       Impact factor: 17.956

5.  Predictions for future human influenza pandemics.

Authors:  R G Webster
Journal:  J Infect Dis       Date:  1997-08       Impact factor: 5.226

6.  Cross-protection and reassortment studies with avian H2 influenza viruses.

Authors:  N V Kaverin; Y A Smirnov; E A Govorkova; I A Rudneva; A K Gitelman; A S Lipatov; N L Varich; S S Yamnikova; N V Makarova; R G Webster; D K Lvov
Journal:  Arch Virol       Date:  2000       Impact factor: 2.574

Review 7.  Realities and enigmas of human viral influenza: pathogenesis, epidemiology and control.

Authors:  Maurice R Hilleman
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

8.  Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines.

Authors:  Balaji Manicassamy; Rafael A Medina; Rong Hai; Tshidi Tsibane; Silke Stertz; Estanislao Nistal-Villán; Peter Palese; Christopher F Basler; Adolfo García-Sastre
Journal:  PLoS Pathog       Date:  2010-01-29       Impact factor: 6.823

9.  Identification of H2N3 influenza A viruses from swine in the United States.

Authors:  Wenjun Ma; Amy L Vincent; Marie R Gramer; Christy B Brockwell; Kelly M Lager; Bruce H Janke; Phillip C Gauger; Devi P Patnayak; Richard J Webby; Jürgen A Richt
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-18       Impact factor: 11.205

10.  Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses.

Authors:  Jens C Krause; Terrence M Tumpey; Chelsey J Huffman; Patricia A McGraw; Melissa B Pearce; Tshidi Tsibane; Rong Hai; Christopher F Basler; James E Crowe
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103
  10 in total
  40 in total

1.  Antibody prevalence to the 2009 pandemic influenza A (H1N1) virus in Germany: geographically variable immunity in winter 2010/2011.

Authors:  Anne Hackenberg; Gökhan Arman-Kalcek; Jens Hiller; Gülsah Gabriel
Journal:  Med Microbiol Immunol       Date:  2012-06-10       Impact factor: 3.402

2.  H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.

Authors:  Irina Isakova-Sivak; Marina Stukova; Mariana Erofeeva; Anatoly Naykhin; Svetlana Donina; Galina Petukhova; Victoria Kuznetsova; Irina Kiseleva; Tatiana Smolonogina; Irina Dubrovina; Maria Pisareva; Alexandra Nikiforova; Maureen Power; Jorge Flores; Larisa Rudenko
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Factors mediating seasonal and influenza A (H1N1) vaccine acceptance among ethnically diverse populations in the urban south.

Authors:  Paula M Frew; Julia E Painter; Brooke Hixson; Carolyn Kulb; Kathryn Moore; Carlos del Rio; Alejandra Esteves-Jaramillo; Saad B Omer
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

4.  International society for disease surveillance conference 2011: building the future of public health surveillance.

Authors:  Daniel B Neill; Karl A Soetebier
Journal:  Emerg Health Threats J       Date:  2011-12-06

5.  Evaluation of multivalent H2 influenza pandemic vaccines in mice.

Authors:  Brian J Lenny; Stephanie Sonnberg; Angela F Danner; Kimberly Friedman; Richard J Webby; Robert G Webster; Jeremy C Jones
Journal:  Vaccine       Date:  2017-02-08       Impact factor: 3.641

6.  Cleavage activation of the human-adapted influenza virus subtypes by matriptase reveals both subtype and strain specificities.

Authors:  Brian S Hamilton; David W J Gludish; Gary R Whittaker
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

7.  Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity.

Authors:  Peter S Lee; Reiko Yoshida; Damian C Ekiert; Naoki Sakai; Yasuhiko Suzuki; Ayato Takada; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-01       Impact factor: 11.205

8.  Swine Influenza Virus PA and Neuraminidase Gene Reassortment into Human H1N1 Influenza Virus Is Associated with an Altered Pathogenic Phenotype Linked to Increased MIP-2 Expression.

Authors:  Daniel Dlugolenski; Les Jones; Elizabeth Howerth; David Wentworth; S Mark Tompkins; Ralph A Tripp
Journal:  J Virol       Date:  2015-03-11       Impact factor: 5.103

9.  The Molecular Basis for Antigenic Drift of Human A/H2N2 Influenza Viruses.

Authors:  M Linster; E J A Schrauwen; S van der Vliet; D F Burke; P Lexmond; T M Bestebroer; D J Smith; S Herfst; B F Koel; R A M Fouchier
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

Review 10.  Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies.

Authors:  Peter S Lee; Ian A Wilson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.